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as having a concomitant infection with  C. difficile . Six pa-
tients were female and the median age was 49 years (range: 
15–80). Six patients with  C. difficile infections suffered from 
UC and 4 patients from CD, all with previous colonic involve-
ment. Eight patients used immunosuppressive therapies; 
only 2 patients were treated with antibiotics before infec-
tion.  Conclusion: In contrast to recent reports from other 
countries, only a low percentage of hospitalized patients 
with acute flares of their IBD were identified as having an 
underlying  C. difficile infection in this German tertiary refer-
ral center. However, in IBD patients with an acute flare, a con-
comitant  C. difficile infection should be excluded, especially 
in patients with immunosuppressive treatment and colonic 
involvement of their disease. Further research is needed to 
evaluate if regions with different risks of  C. difficile infections 
exist and to find out more about potential reasons for this 
observation.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 A large number of reports from many different regions 
have documented the rising incidence of  Clostridium
difficile infections during the last decade  [1, 2] . Elderly 
patients are particularly susceptible to infections; addi-
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 Abstract 
 Introduction: Many reports, mainly from the US and Canada 
but also a recent report from a center in Europe, have docu-
mented the increasing impact of  Clostridium difficile infec-
tions in patients with inflammatory bowel disease (IBD) dur-
ing the last years. To determine the prevalence of  C. difficile 
infections in hospitalized IBD patients in a tertiary referral 
center in Germany, we conducted this retrospective analysis. 
 Methods: Data of all IBD in-patients treated due to an acute 
flare of their IBD at the Department of Internal Medicine I of 
the University of Regensburg between January 1, 2001, and 
June 30, 2008, were analyzed. In patients with a concomitant 
diagnosis of  C. difficile infection, further variables such as 
IBD-related treatment at the time of infection or outcome 
were examined.  Results: In total, 995 in-patients with IBD 
were treated in this hospital [638 patients with Crohn’s dis-
ease (CD), 357 with ulcerative colitis (UC)] during the study 
period. Of these, 279 patients with CD and 242 patients with 
UC were admitted with an acute flare and suffering from di-
arrhea and abdominal pain. Only 10 of those were diagnosed 
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tionally, factors like recent use of antibiotics and im -
mu nosuppressive drugs and systemic comorbidities are 
suggested to increase the risk of  C. difficile  infection  [2] .
 After regional outbreaks of  C. difficile in the US, Can-
ada and subsequently in parts of Europe, a hypervirulent 
epidemic strain of  C. difficile (North American pulsed-
field type 1, PCR ribotype 027) resistant to fluroquino-
lone attracted a great deal of attention  [3–5] .
 As patients with inflammatory bowel disease (IBD) – 
comprising Crohn’s disease (CD) and ulcerative colitis 
(UC) – frequently present with diarrhea and abdominal 
pain, differentiation between an acute flare and enteric 
infection seems to be necessary in this setting. This is 
even more so since several studies, mainly from the US 
and Canada, have documented a dramatic rise of  C. dif-
ficile infections in patients with IBD, both in studies from 
tertiary referral centers and in national surveys  [6–10] . 
More recently, an increasing incidence in IBD patients 
has also been identified in Greece  [11] and Belgium  [12] , 
as well as a high prevalence of  C. difficile infection in Ital-
ian pediatric IBD patients  [13] .
 However, data on the impact of  C. difficile infections 
in adult IBD patients from other centers in Europe are 
missing. Therefore, the purpose of this retrospective 
study was to assess the prevalence of  C. difficile infections 
in patients with IBD in a tertiary center in Germany.
 Study Cohort 
 All in-patients treated for an acute flare of their IBD at the De-
partment of Internal Medicine I of the University of Regensburg 
between January 1, 2001, and June 30, 2008, were included in this 
retrospective analysis. Every single admission of a patient was 
evaluated separately if the patient was admitted to our depart-
ment more than once. Patients hospitalized only due to disease 
complications (e.g. fistulas or extraintestinal manifestations), but 
not suffering from diarrhea, were excluded from this study. 
 The University of Regensburg is a tertiary referral center 
which treated 29,162 in-patients in 2007, 3,690 of whom were 
treated at the Department of Internal Medicine I. IBD patients are 
referred to this institution from primary care physicians as well 
as from secondary and primary centers. 
 The diagnosis of CD, UC or indeterminate colitis was based 
on endoscopic, histological and radiological findings.
 For all patients included in the study, computer-based dis-
charge registries were searched using text searches for ‘ Clostrid-
ium difficile ’, ‘ C. difficile ’ or ‘ C. diff. ’ to identify patients with this 
concomitant diagnosis. Patient records were checked to identify 
every patient which was tested for  C. difficile infection during the 
relevant hospitalization. The diagnosis of  C. difficile infection 
was made by stool toxin analysis (ELISA stool toxin A and B) and/
or histological evidence with classic pseudomembrane forma-
tions.
 In patients with a concomitant diagnosis of  C. difficile infec-
tion, further demographic data such as age, time since first diag-
nosis of IBD, clinical symptoms, IBD-related treatment at time of 
infection, nosocomial infection, season at time of infection, treat-
ment for  C. difficile infection and outcome were collected.
 Statistical analyses were performed using SPSS software (16.0, 
Chicago, Ill., USA).
 Results 
 Basic Characteristics 
 During the study period between January 1, 2001, and 
June 30, 2008, 995 in-patients with IBD were treated in 
this hospital (638 patients with CD, 357 with UC). In 279 
patients with CD and 242 patients with UC, an acute flare 
with typical symptoms of diarrhea and abdominal pain 
was the reason for hospital admission. Other reasons for 
admission were fistulas or extraintestinal manifesta-
tions. Patients treated due to disease complications were 
not included in this analysis.
 In all IBD patients with an acute flare, 438 stool tests 
on pathogenic intestinal bacteria were performed (82.5%). 
248 patients were tested particularly with regard to  C. dif-
ficile by stool toxin analysis (47.6% of all patients), with 
120 patients diagnosed as having CD, and 128 patients 
diagnosed with UC. The number of tests per year in IBD 
patients with a flare of their disease is presented in  table 1 .
 In total, 3,267 samples from all the patients treated at 
the Department of Internal Medicine I – including non-
IBD patients – were tested for  C. difficile during the study 
period at the Institute for Microbiology and Hygiene. In 
this entire population, an increase of  C. difficile infec-
tions was observed, peaking in 2005 with positive test 
results in 12.7% of the patients. Between 2001 and 2004, 
93 of 1,661 tests on  C. difficile infections were positive, 
and between 2005 and 2008, 166 of 1,606 tests showed 
positive results (p  ! 0.0001, Fisher’s exact test).
 IBD Patients with  C. difficile Infection 
 Only 10 of all the IBD patients with symptoms of an 
acute flare with diarrhea were diagnosed as having a con-
comitant infection with  C. difficile (3.9% of all tested IBD 
patients). In 9 of the 10 patients, the diagnosis of  C. dif-
ficile infection was confirmed by stool toxin analysis; in 
1 patient the diagnosis was made endoscopically and his-
tologically despite negative stool toxin analysis. 
 Of the 10 patients, 6 were female and the median age 
was 49 years (range: 15–80). Six patients with  C. difficile 
infections had UC (2.7% of all tested patients with UC). 
Of the remaining 4 CD patients (4% of all tested patients 
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with CD), 1 patient showed a superinfection with  C. dif-
ficile at the time of first diagnosis of IBD. In 2 patients, 
both of whom had UC, the time of first diagnosis of IBD 
was less than 1 year before infection with  C. difficile . In 
addition, patients with a history of IBD stretching back 
more than 10 years were affected. Interestingly, in all pa-
tients with CD, involvement of the colon was document-
ed ( table 2 ).
 Medication at Time of Infection 
 Eight patients with concomitant  C. difficile infection 
had immunosuppressive therapies such as corticoste-
roids (6 patients) or azathioprine (2 patients) at the time 
of infection. Only 2 patients were treated with antibiotics 
before  C. difficile infection was diagnosed, and one of 
these patients was simultaneously treated with azathio-
prine ( fig. 1 ). No patient was on anti-TNF therapy. There 
was no seasonal variation of  C. difficile infections ( fig. 2 ). 
 One infection was found each during the years 2001–
2004 and 2006–2007 and 2 infections each during 2005 
and 2008. Comparing the first 4 years (2001–2004) to the 
next 3.5 years (2005–2008) of the observation period, no 
statistically significant difference between the two peri-
ods was seen (p = 0.21, Fisher’s exact test).
 Outcome 
 All patients were successfully treated with metronida-
zole, except for the patient with concomitant  C. difficile 
infection at the time of first diagnosis of CD. In this pa-
tient, a total proctocolectomy became necessary due to 
toxic megacolon. All other patients showed remission of 
symptoms during antibiotic therapy. Additionally, in 7 
patients, stool toxin was negative after withdrawal of 
metronidazole. None of the patients revealed a recur-
rence of episodes of  C. difficile infections after primary 
treatment.
 Discussion 
 In this retrospective observational study over a 7-year 
period, we found only a few hospitalized patients with 
IBD and concomitant  C. difficile infection in this tertiary 
referral center. These results are even more interesting 
since the incidence of  C. difficile  infections in the total 
patient population in this department showed a signifi-
cant increase during the study period, which is similar to 
results from other centers. Our observation with regard 
to IBD patients therefore stands in contrast to several re-
ports, mainly from North America.
 An alarming rise in the incidence and prevalence of
 C. difficile infections in IBD patients has been described 
both in studies from single tertiary specialty centers and 
reports using nationwide databases  [6–10] . Worse out-
comes and higher mortality were also seen in patients 
with  C. difficile infections and underlying IBD with a ris-
ing case fatality during the later years  [7, 9] . In our series, 
we could not find an increase of  C. difficile infections in 
our patients during the observation time in spite of rising 
awareness of possible infections in the later years. This is 
Table 1. T ested patients with flare-ups per year
Year Number 
of flare-ups
Number of tests
on C. difficile
Patients with 
flare tested, %
2001 96 43 44.8
2002 66 34 51.5
2003 79 31 39.2
2004 73 28 38.4
2005 66 26 39.4
2006 53 27 50.9
2007 59 36 61.0
2008 (until June 30) 29 23 79.3
71
1 1
Immunosuppressive
therapy
Immunosuppressive
therapy and antibiotics
Only antibiotics
No therapy
 Fig. 1. Therapy at time of infection. 
3
3
2
2
Spring
Summer
Fall
Winter
 Fig. 2. Season at time of infection. 
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Table 3. S ummary of the existing literature
First author Patient population Testing methods Incidence or prevalence of
C. difficile infection
Trends of C. difficile infections
Rodemann [6] IBD vs. non-IBD stool toxin analysis doubled in CD, tripled in UC increasing
Ananthakrishnan [7] IBD vs. non-IBD n.a. n.a. increasing, IBD associated with 
worse outcome
Nguyen [8] IBD vs. non-IBD n.a. doubled in UC increasing, IBD associated with 
higher mortality in UC
Ricciardi [9] IBD vs. non-IBD,
national survey
n.a. rising in UC and CD with
colonic involvement
UC with increasing case fatality
Issa [10] IBD, referral center stool toxin analysis doubled in IBD use of immunosuppressive 
drugs and colonic involvement 
as risk factors
Bossuyt [12] IBD vs. non-IBD stool toxin analysis 3.75-fold increase use of immunosuppressive 
drugs not influencing the risk
Pascarella [13] pediatric IBD vs.
non-IBD, single-center
stool toxin analysis higher prevalence in IBD vs. 
non-IBD
Mylonaki [15] IBD, acute flare stool toxin analysis 5.5% over 5-year period
Ott (this study) IBD, acute flare stool toxin analysis,
flexible sigmoidoscopy
3.9% over 7.5-year period
n.a. = Not applicable.
Table 2.  Characteristics of all patients with C. difficile infection and IBD
Gender Kind of IBD Age
years
Developed
C. difficile during
hospital stay1
Symptoms Therapy Time since first 
diagnosis of IBD
Colonic 
involve-
ment
Female UC (pancolitis) 51.0 no watery diarrhea metronidazole <1 year yes
Male CD 47.0 yes toxic megacolon surgery at first diagnosis yes
Female UC (left-sided) 30.0 no watery diarrhea, 
abdominal pain
metronidazole >10 years yes
Female UC (pancolitis) 15.0 no watery diarrhea metronidazole <1 year yes
Male UC (pancolitis) 52.0 yes fever metronidazole >10 years yes
Female CD 47.0 no watery diarrhea metronidazole >10 years yes
Male UC (proctitis) 60.0 no watery diarrhea metronidazole 1–3 years yes
Female UC (pancolitis) 80.0 yes watery diarrhea metronidazole 5–10 years yes
Female CD 72.0 no watery diarrhea, 
abdominal pain, fever
metronidazole 3–5 years yes
Male CD 28.0 no watery diarrhea, 
abdominal pain
metronidazole >10 years yes
1 Defined as primary negative test result with a subsequent positive result during the hospital stay.
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confirmed by our data showing an increasing percentage 
of IBD patients with flare being tested, especially since 
2006. In addition, we could not find a seasonal variation 
of  C. difficile infection, although it has been described in 
previous studies with a lower risk of infection in summer 
months  [8, 14] . A summary of the existing literature on 
 C. difficile infections in IBD patients is given in  table 3 . 
 Mylonaki et al. [15] found 5.5% of the relapses in IBD 
patients to be associated with  C. difficile infections in 
their case series from Great Britain, which is comparable 
to the results obtained in our retrospective study (3.9% of 
all tested IBD patients with diarrhea). In contrast to their 
study, where 60% of the patients with an acute flare were 
tested for  C. difficile toxin, we tested for  C. difficile infec-
tion in only 48% of the patients with a diarrheal flare. Not 
testing all the patients with diarrhea has to be considered 
the main limitation of our study, despite the increasing 
numbers of patients with acute flares being tested during 
the later years.
 In this context, possible underdiagnosing of  C. difficile 
infection might be caused by the application of antibiotic 
therapy without prior testing. In our series, a total num-
ber of 92 of 521 flares (17.6%) were treated with antibiotic 
therapy, although no test on  C. difficile was performed.
 Another limitation was the toxin-based ELISA used 
for testing in our study, which is known to be less sensi-
tive (70–90%) than cytotoxicity tests. Repeated testing 
has been shown to increase the diagnostic yield to up to 
92–95%  [1, 16] . Nevertheless, there are some controversies 
on repeated testing for  C. difficile infection. In their study, 
Nemat et al.  [17] showed a low value of repeated tests, and 
repeated testing has been suggested to result in false-pos-
itive tests  [18] . Therefore, a clear guideline recommend-
ing the optimal number of tests still does not exist. At our 
department, initially one test is performed in IBD pa-
tients with diarrhea. If the patient does not respond to 
anti-inflammatory treatment, a second stool test is or-
dered as well as endoscopic investigations, which led to 
the diagnosis in one of our patients despite negative stool 
toxin analysis.
 The varying incidence of  C. difficile infections in dif-
ferent countries might partly be explained by differences 
of the examined patient populations. For example, differ-
ent strategies in the treatment of patients with IBD, e.g. 
the frequent use of anti-TNF therapies in several coun-
tries, might play a role. A previous report identified im-
munosuppressive therapies as an important predisposing 
factor for  C. difficile infections  [19] . This is supported by 
our results as 80% of our positive patients received im-
munosuppressive therapy prior to the diagnosis of  C. 
 difficile infection. Surprisingly, prior use of antibiotics, 
which is known as the main cause for  C. difficile infection 
in the general population was only found in 2 patients  [2] . 
Although  C. difficile infections may not be limited to the 
colon  [1, 20] , in all of our patients with CD, colonic in-
volvement was seen. Therefore, one may speculate that in 
addition to UC patients, CD patients with colonic in-
volvement are at a higher risk for  C. difficile infection. 
This observation is consistent with results of earlier stud-
ies identifying colonic disease as a risk factor for  C. dif-
ficile infection  [8, 9] .
 Conclusion 
 In this German tertiary referral center only a low per-
centage of hospitalized patients with IBD were found to 
have a concomitant  C. difficile infection. Therefore, in 
contrast to reports from North America and Belgium, 
IBD patients hospitalized due to an acute flare have only 
a moderate risk for  C. difficile infection in our region. 
This observation suggests the possibility that low- and 
high-risk areas for  C. difficile infections might exist. As 
this is the first study showing possible geographic varia-
tion, further research on underlying reasons is needed.
 Nevertheless, in clinical practice in all IBD patients 
with an acute diarrheal flare, a superinfection with  C. dif-
ficile should be excluded. This is of special importance in 
patients with immunosuppressive treatment and colonic 
involvement to prevent medical malpractice using detri-
mental immunosuppressive therapies in  C. difficile -in-
fected IBD patients, shorten the time of hospitalization 
and improve patient outcome.
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